Back to Search
Start Over
Letter: potential selection bias in real‐world comparison of ustekinumab versus vedolizumab as a second‐line treatment for Crohn's disease—authors' reply.
- Source :
-
Alimentary Pharmacology & Therapeutics . Apr2022, Vol. 55 Issue 8, p1070-1071. 2p. - Publication Year :
- 2022
-
Abstract
- LINKED CONTENT: This article is linked to Lenti et al papers. To view these articles, visit https://doi.org/10.1111/apt.16742 and https://doi.org/10.1111/apt.16871 [ABSTRACT FROM AUTHOR]
- Subjects :
- *VEDOLIZUMAB
Subjects
Details
- Language :
- English
- ISSN :
- 02692813
- Volume :
- 55
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- Alimentary Pharmacology & Therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 156056843
- Full Text :
- https://doi.org/10.1111/apt.16896